The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial
Abstract
Background Lysyl oxidase-like 2 (LOXL2) catalyses collagen cross-linking and is implicated in the pathogenesis of idiopathic pulmonary fibrosis (IPF). The aim of this study was to investigate the efficacy and safety of simtuzumab, a monoclonal antibody against LOXL2, in patients with IPF. Methods In this randomised, double-blind, phase 2 trial, we recruited patients aged 45-85 years with definite IPF diagnosed prior to 3 years of screening from 183 hospitals and respiratory clinics in 14 countries. Eligible patients, stratified by baseline forced vital capacity (FVC), serum LOXL2 (sLOXL2) concentrations, and pirfenidone and nintedanib use, were randomly assigned (1:1) to inject 125 mg/mL simtuzumab or placebo subcutaneously once a week. The primary endpoints were progression-free survival, defined as time to all-cause death or a categorical decrease from baseline in FVC % predicted, in the intention-to-treat population, in patients with sLOXL2 concentrations in the 50th percentile or higher, and in patients with sLOXL2 concentrations in the 75th percentile or higher. Treatment duration was event-driven, and interim analyses were planned and conducted after approximately 120 and 200 progression-free survival events, respectively, occurred. We compared treatment groups with the stratified log-rank test. This study is registered with ClinicalTrials.gov, number NCT01769196. Findings Patients with IPF were recruited between Jan 31, 2013, and June 1, 2015. The intention-to-treat po…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systemic corticosteroids have been widely studied in the treatment of IPF with systematic reviews and meta-analyses failing to show any therapeutic benefit [23,52,53].”
From Emerging pharmacological options in the treatment of idiopathic pulmonary fibrosis (IPF) (2024) · cites this paper as [52]
Citations
Cites
Raghu, G., Collard, H. R., Egan, J. J., Martinez, F. J., Behr, J., Brown, K. K., Colby, T. V., Cordier, J.-F., Flaherty, K. R., Lasky, J. A., et al. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.2009-040gl · Cited by 7,186
Self-citationEfficacy and Safety of Nintedanib in Idiopathic Pulmonary Fibrosis
Richeldi, L., du Bois, R. M., Raghu, G., Azuma, A., Brown, K. K., Costabel, U., Cottin, V., Flaherty, K. R., Hansell, D. M., Inoue, Y., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402584 · Cited by 4,654
Self-citationA phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
King, T. E., Bradford, W. Z., Castro-Bernardini, S., Fagan, E. A., Glaspole, I., Glassberg, M. K., Gorina, E., Hopkins, P. M., Kardatzke, D., Lancaster, L., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1402582 · Cited by 3,975
Self-citationRaghu, G., Rochwerg, B., Zhang, Y., Garcia, C. A. C., Azuma, A., Behr, J., Brozek, J. L., Collard, H. R., Cunningham, W., Homma, S., et al. (2015) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201506-1063st · Cited by 1,916
Self-citationMoeller, A., Ask, K., Warburton, D., Gauldie, J., & Kolb, M. (2008) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.08.011 · Cited by 1,007
Barry-Hamilton, V., Spangler, R., Marshall, D., McCauley, S., Rodriguez, H. M., Oyasu, M., Mikels, A., Vaysberg, M., Ghermazien, H., Wai, C., et al. (2010) · Nature Medicine · doi:10.1038/nm.2208 · Cited by 870
Self-citationAnimal Models of Fibrotic Lung Disease
B. Moore, B., Lawson, W. E., Oury, T. D., Sisson, T. H., Raghavendran, K., & Hogaboam, C. M. (2013) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2013-0094tr · Cited by 412
Forced Vital Capacity in Idiopathic Pulmonary Fibrosis — FDA Review of Pirfenidone and Nintedanib
Karimi-Shah, B. A., & Chowdhury, B. A. (2015) · New England Journal of Medicine · doi:10.1056/nejmp1500526 · Cited by 316
Scraping fibrosis: Expressway to the core of fibrosis
Mehal, W. Z., Iredale, J., & Friedman, S. L. (2011) · Nature Medicine · doi:10.1038/nm0511-552 · Cited by 211
Transglutaminase 2 and Its Role in Pulmonary Fibrosis
Olsen, K. C., Sapinoro, R. E., Kottmann, R. M., Kulkarni, A. A., Iismaa, S. E., Johnson, G. V. W., Thatcher, T. H., Phipps, R. P., & Sime, P. J. (2011) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.201101-0013oc · Cited by 184
Cited by
Extracellular Matrix in the Tumor Microenvironment and Its Impact on Cancer Therapy
Henke, E., Nandigama, R., & Ergün, S. (2020) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2019.00160 · Cited by 1,142
Lampi, M. C., & Reinhart-King, C. A. (2018) · Science Translational Medicine · doi:10.1126/scitranslmed.aao0475 · Cited by 551
Organ and tissue fibrosis: Molecular signals, cellular mechanisms and translational implications
Weiskirchen, R., Weiskirchen, S., & Tacke, F. (2019) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2018.06.003 · Cited by 538
Inflammation and immunity in IPF pathogenesis and treatment
Heukels, P., Moor, C. C., von der Thüsen, J. H., Wijsenbeek, M. S., & Kool, M. (2019) · Respiratory Medicine · doi:10.1016/j.rmed.2018.12.015 · Cited by 517
Determinants of Fibrosis Progression and Regression in NASH
Schuppan, D., Surabattula, R., & Wang, X. Y. (2018) · Journal of Hepatology · doi:10.1016/j.jhep.2017.11.012 · Cited by 479
“These disappointing results may have been both due to limited penetration of the antibody into human scar tissue and to relative inefficiency to neutralize the target, since preclinical data indicate that Loxl-2 and general Lox-inhibition effectively prevent liver fibrosis progression and facilitate its reversal, incl…”
Background
Metadata
- Authors
- Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., Wells, A. U., Whelan, T. P. M., Wuyts, W., Moreau, E., Patterson, S. D., Smith, V., Bayly, S., Chien, J. W., Gong, Q., Zhang, J. J., & O'Riordan, T. G.
- Affiliations
- University of Washington (US)
- University of California, San Francisco (US)
- Université de Lyon (FR)
- University of Pittsburgh (US)
- Weill Cornell Medicine (US)
- Columbia University Irving Medical Center (US)
- Cedars-Sinai Medical Center (US)
- Asan Medical Center (KR)
- Royal Brompton Hospital (GB)
- Medical University of South Carolina (US)
- KU Leuven (BE)
- bioMérieux (France) (FR)
- Gilead Sciences (United States) (US)
- Corresponding author
- Raghu, Ganesh
- ORCID
- Venue
- The Lancet Respiratory Medicine
- Publisher
- Elsevier BV
- Published
- 2017-01
- Volume
- 5
- Issue
- 1
- Pages
- 22-32
- ISSN
- 2213-2600 (ISSN-L)
- OpenAlex
- W2560640434
- Cited by
- 278
- References
- 17
- Citations by year
- 2026: 24 · 2025: 16 · 2024: 36 · 2023: 26 · 2022: 25 · 2021: 21 · 2020: 27 · 2019: 29 · 2018: 40 · 2017: 32
- FWCI
- 30.17
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- Locations
- The Lancet Respiratory Medicine (publishedVersion)
- PubMed (publishedVersion)
- Lirias (submittedVersion)
- Funders
- Gilead Sciences
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Chronic Obstructive Pulmonary Disease (COPD) Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Pulmonary Hypertension Research and Treatments
- Keywords
- idiopathic pulmonary fibrosis, LOXL2, monoclonal antibodies, collagen cross-linking, progression-free survival, forced vital capacity decline, treatment safety, anti-drug antibodies, pulmonary hypertension, pulmonary arterial hypertension
- MeSH terms
- Aged, Aged, 80 and over, Amino Acid Oxidoreductases, Double-Blind Method, Drug Administration Schedule, Enzyme Inhibitors, Female, Humans, Indoles, Male, Middle Aged, Pyridones, Treatment Outcome, Disease-Free Survival, Idiopathic Pulmonary Fibrosis, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1016/s2213-2600(16)30421-0
- The paper
- Raghu, G., Brown, K. K., Collard, H. R., Cottin, V., Gibson, K. F., Kaner, R. J., Lederer, D. J., Martinez, F. J., Noble, P. W., Song, J. W., Wells, A. U., Whelan, T. P. M., Wuyts, W., Moreau, E., Patterson, S. D., Smith, V., Bayly, S., Chien, J. W., Gong, Q., . . . O'Riordan, T. G. (2017). Efficacy of simtuzumab versus placebo in patients with idiopathic pulmonary fibrosis: a randomised, double-blind, controlled, phase 2 trial. The Lancet Respiratory Medicine. https://doi.org/10.1016/s2213-2600(16)30421-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.